Latham & Watkins Advises the Underwriters in Kaleido Biosciences’ Public Offering

A capital markets team represented the underwriters in the clinical-stage healthcare company’s offering.

June 04, 2020

Kaleido Biosciences, Inc., a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, has closed an underwritten public offering of 4,750,000 shares of its common stock at a public offering price of US$7.50 per share. In addition, Kaleido has granted the underwriters a 30-day option to purchase up to an additional 712,500 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Kaleido from this offering were approximately US$35.6 million. 

Latham & Watkins LLP represented the underwriters in the offering with a capital markets team led by partners Peter Handrinos and Wesley Holmes, with associates Samuel Niles and Emily Henderson. Advice was also provided on regulatory matters by partner Ben Haas, with associate Barrett Tenbarge; on intellectual property matters by partner Alan Tamarelli, with associate Jiqiang Lin; and on tax matters by partner Jocelyn Noll, with associate Joseph Curran.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.